June 9 (Reuters) - A Canadian team hopes to revive a heart drug ditched by Roche three years ago by running a major clinical trial targeting only those patients with the right genetic profile to benefit from its ability to boost “good” cholesterol.
The Swiss drugmaker, which has licensed rights to dalcetrapib to Quebec-based DalCor Pharmaceuticals, said on Tuesday it would provide a companion diagnostic for use in the Phase III study.
DalCor estimates about $250 million will be needed for the project, which will be run in collaboration with the Montreal Heart Institute (MHI) and will screen more than 30,000 patients in 30 countries to find 5,000 with the right genetic profile.
Help employers find you! Check out all the jobs and post your resume.
